AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
Filed with Euronext · · 8 pages · English
Summary by 6ix AI
The company experienced an operating loss primarily due to a provision related to a tax credit dispute, while its cash position reflects recent capital raises through private placements. The filing also highlights the granting of patents for masitinib in treating multiple sclerosis and prostate cancer, enhancing the company's intellectual property portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AB Science
- AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
- AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques
- AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
- AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
- AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
Later from AB Science
- Revenues for the first half of 2026 and update on AB Science’s activities
- AB Science will hold a web conference on Wednesday, October 14, 2026, from 6: 00 p.m. to 7: 30 p.m.
Follow AB Science into a list and get an email when it puts out news.
Follow AB Science